Compare Carnival Corp (CCL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carnival Corp vs TransMedics Group Inc — how do they compare? Carnival Corp trades at $27.8 (market cap $37.98B), while TransMedics Group Inc trades at $87.19 (market cap $3.10B). The key difference: Carnival Corp is far larger — about 12.3× TransMedics Group Inc's market cap, and Carnival Corp pays a 1.62% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| CCL | TMDX | |
|---|---|---|
Market Cap | $37.98B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $33.99 | $150.42 |
52-Week Low | $23.89 | $61.99 |
Enterprise Value | $61.91B | $3.49B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $27.82, showing modest daily gains of 0.25%. The stock maintains strong fundamental momentum with consecutive earnings beats in recent quarters (Q4 2025 and Q1 2026) and improving profitability trends. Technical indicators show a bearish bias in moving averages while oscillators remain neutral. The company demonstrates robust operational recovery with revenue growth from $12.2B in 2022 to $26.6B in 2025, and positive net cash flow of $727M in 2025 after years of negative cash flow.
CCL presents a compelling recovery story with analyst consensus pointing to 26% upside to the $35.18 price target. Investment opportunities include sustained travel demand, fleet expansion, and debt reduction progress. Key risks involve fuel price volatility, competitive pressures, and execution of growth initiatives amid economic uncertainty. The stock's attractive valuation (P/E 12.49x) and 59.6% analyst buy rating support a positive medium-term outlook.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
